About this trial
Critically ill patients admitted to intensive care units (ICUs) are predisposed to upper gastrointestinal (GI) bleeding secondary to stress-related mucosal damage. The two most significant independent risk factors for stress ulceration and subsequent GI bleeding in this setting are mechanical ventilation and coagulopathy.1,2 Observational data indicate that proton pump inhibitors (PPIs) remain the most frequently employed prophylactic agents in the ICU.3
Comparative studies evaluating the efficacy of PPIs have shown a positive correlation between their pharmacokinetic properties and acid-suppressive activity. Among available PPIs, esomeprazole demonstrates superior pharmacokinetic characteristics, translating into more effective acid control in clinical use.7,8 In fact, one study reported that the area under the curve (AUC) for esomeprazole was nearly twice that of omeprazole at equivalent doses (14), supporting its enhanced acid-suppressive effect and prolonged maintenance of intragastric pH \> 4.9
Eligibility criteria
Qualifiers
Adult patients aged 18-75 years admitted to an ICU post-surgery.
Non-esophagogastric post-surgical patients.
An anticipated ICU stay for at least 72 hours.
Willing to provide consent.
Disqualifiers
Allergy to the study medications or excipients
Need for enteral feeding
Estimated survival of <96 hours
Pregnant and breastfeeding females.
Trial design
Treatments tested in this trial
- Esomeprazole